PK and Dose Escalation and Expansion Study of DST-2970 (clinicaltrials.gov)
P1, N=26, Terminated, DisperSol Technologies, LLC | N=54 --> 26 | Active, not recruiting --> Terminated; Dose escalation portion of the study completed, one expansion cohort was eliminated due to change in standard of care, and the second cohort was not enrolled based on future development considerations.